File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Germline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families

TitleGermline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families
Authors
KeywordsChinese
germline mutation
hereditary breast and ovarian cancers
RAD51C
RAD51D
Issue Date16-Aug-2024
PublisherMDPI
Citation
Journal of Personalized Medicine, 2024, v. 14, n. 8 How to Cite?
Abstract

Background: RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest. Methods: We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC). Results: We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD). Conclusions: Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.


Persistent Identifierhttp://hdl.handle.net/10722/353310
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.736

 

DC FieldValueLanguage
dc.contributor.authorKwong, Ava-
dc.contributor.authorHo, Cecilia Yuen Sze-
dc.contributor.authorAu, Chun Hang-
dc.contributor.authorTey, Sze Keong-
dc.contributor.authorMa, Edmond Shiu Kwan-
dc.date.accessioned2025-01-17T00:35:30Z-
dc.date.available2025-01-17T00:35:30Z-
dc.date.issued2024-08-16-
dc.identifier.citationJournal of Personalized Medicine, 2024, v. 14, n. 8-
dc.identifier.issn2075-4426-
dc.identifier.urihttp://hdl.handle.net/10722/353310-
dc.description.abstract<p>Background: RAD51C and RAD51D are crucial in homologous recombination (HR) DNA repair. The prevalence of the RAD51C and RAD51D mutations in breast cancer varies across ethnic groups. Associations of RAD51C and RAD51D germline pathogenic variants (GPVs) with breast and ovarian cancer predisposition have been recently reported and are of interest. Methods: We performed multi-gene panel sequencing to study the prevalence of RAD51C and RAD51D germline mutations among 3728 patients with hereditary breast and/or ovarian cancer (HBOC). Results: We identified 18 pathogenic RAD51C and RAD51D mutation carriers, with a mutation frequency of 0.13% (5/3728) and 0.35% (13/3728), respectively. The most common recurrent mutation was RAD51D c.270_271dupTA; p.(Lys91Ilefs*13), with a mutation frequency of 0.30% (11/3728), which was also commonly identified in Asians. Only four out of six cases (66.7%) of this common mutation tested positive for homologous recombination deficiency (HRD). Conclusions: Taking the family studies in our registry and tumor molecular pathology together, we concluded that this relatively common RAD51D variant showed incomplete penetrance in our local Chinese community. Personalized genetic counseling emphasizing family history for families with this variant, as suggested at the UK Cancer Genetics Group (UKCGG) Consensus meeting, would also be appropriate in Chinese families.</p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofJournal of Personalized Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChinese-
dc.subjectgermline mutation-
dc.subjecthereditary breast and ovarian cancers-
dc.subjectRAD51C-
dc.subjectRAD51D-
dc.titleGermline RAD51C and RAD51D Mutations in High-Risk Chinese Breast and/or Ovarian Cancer Patients and Families-
dc.typeArticle-
dc.identifier.doi10.3390/jpm14080866-
dc.identifier.scopuseid_2-s2.0-85202608419-
dc.identifier.volume14-
dc.identifier.issue8-
dc.identifier.eissn2075-4426-
dc.identifier.issnl2075-4426-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats